Prospective Evaluation of Quality of Life and Neurocognitive Effects in Patients With Multiple Brain Metastases Receiving Whole-Brain Radiotherapy With or Without Thalidomide on Radiation Therapy Oncology Group (RTOG) Trial 0118 Academic Article uri icon


MeSH Major

  • Brain Neoplasms
  • Cognition
  • Cognition Disorders
  • Cranial Irradiation
  • Quality of Life


  • Quality of life and neuropsychological testing can be prospectively administered on a Phase III cooperative group trial. The MMSE should be evaluated with adjustments for age and educational level. Baseline SQLI is predictive of survival. Despite neurocognitive declines, QOL remained stable during treatment and follow-up. Poor neurocognitive function may predict clinical deterioration. Lack of an untreated control arm makes it difficult to determine the contribution of the respective interventions (i.e., WBRT, thalidomide) to neurocognitive decline. The RTOG has developed a trial to study the role of preventative strategies aimed at forestalling neurocognitive decline in this population.

publication date

  • May 2008



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ijrobp.2007.09.015

PubMed ID

  • 18164829

Additional Document Info

start page

  • 71

end page

  • 8


  • 71


  • 1